Lamisil

Terbinafine, the active ingredient in Lamisil, is an allylamine antifungal presented as an oral tablet for systemic use. It treats dermatophyte skin infections and fungal nail disease in adult patients. GNH USA supplies Lamisil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamisil is used to treat fungal infections caused by dermatophytes and related organisms. - Tinea pedis: relieves itching and clears fungal infection of the feet. - Tinea corporis: eliminates ring‑shaped skin lesions caused by dermatophytes. - Tinea cruris: treats fungal infection of the groin area. - Onychomycosis: improves appearance and clears fungal infection of the toenails and fingernails.

Terbinafine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Taste disturbance: altered or loss of taste sensation. - Headache: mild to moderate intensity. - Skin rash: localized erythema or pruritus. - Elevated liver enzymes: mild, transient increases in laboratory tests.

Serious or Rare Side Effects: - Hepatotoxicity: signs of liver injury such as jaundice or severe enzyme elevation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Blood dyscrasias: agranulocytosis, thrombocytopenia, or anemia. - Peripheral neuropathy: numbness or tingling in extremities. - Acute interstitial nephritis: kidney inflammation presenting with reduced urine output.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor for adverse events. - Liver function assessment: obtain baseline hepatic enzymes and repeat if symptoms develop. - Skin monitoring: watch for rash, blistering, or signs of severe cutaneous reactions. - Hypersensitivity: avoid use in patients with known terbinafine allergy. - Renal impairment: adjust dosing or monitor renal function in patients with reduced clearance. - Drug interactions: review concomitant medications for potential hepatic or CYP interactions. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Terbinafine can affect the metabolism of several co‑administered drugs, requiring careful management.

Major Interactions (Avoid): - Itraconazole: combined use may increase risk of hepatotoxicity. - Cimetidine: may raise terbinafine plasma concentrations, enhancing toxicity. - CYP2D6 substrates (e.g., tricyclic antidepressants, certain antipsychotics): risk of elevated levels and adverse effects.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR for potential anticoagulant effect changes. - Oral contraceptives: assess efficacy as terbinafine may reduce hormonal levels. - Antiretroviral agents (e.g., protease inhibitors): observe for altered drug exposure. - Statins: watch for increased risk of myopathy. - Rifampicin: may reduce terbinafine effectiveness by inducing metabolism.